ASP Isotopes (ASPI, Financial) has received overwhelming support from Renergen's shareholders for its acquisition of the company. At a meeting on July 10, an impressive 99.80% of voting shareholders backed the proposal. This deal, conducted under the South African Companies Act, will proceed once several conditions, including regulatory approvals and third-party consents, are met. The deadline for these conditions is September 30, which may be extended if necessary. Following this, the acquisition is anticipated to be finalized by the third quarter of 2025.
Renergen, a South African company specializing in liquefied helium and natural gas production, is partly funded by the U.S. due to helium's crucial role in strategic materials. The merger with ASP Isotopes aims to establish a leading global producer of essential materials, including electronic gases, fluorinated products, and isotopically enriched gases. This partnership expects to create a robust supply chain with strong synergies anticipated in 2026.
The combination is projected to significantly boost ASPI's financial metrics, including revenue and earnings per share, starting in 2026. By 2030, the merged entity aims to achieve over $300 million in EBITDA, driven by sales of isotopes, helium, and LNG within South Africa's energy sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for ASP Isotopes Inc (ASPI, Financial) is $7.75 with a high estimate of $11.00 and a low estimate of $4.50. The average target implies an upside of 4.17% from the current price of $7.44. More detailed estimate data can be found on the ASP Isotopes Inc (ASPI) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, ASP Isotopes Inc's (ASPI, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
